Search results
Results from the WOW.Com Content Network
Risk Evaluation and Mitigation Strategies (REMS) is a program of the US Food and Drug Administration for the monitoring of medications with a high potential for serious adverse effects. REMS applies only to specific prescription drugs, but can apply to brand name or generic drugs. [1] The REMS program was formalized in 2007.
REMS are also tailored to the medication (and subsequent side effects) it aims to surveil: For isotretinoin, the program focuses on preventing pregnancy, but for a medication like olanzapine (an ...
The iPLEDGE program was put into place a group formed by the companies that manufactured the drug at the time called the Isotretinoin Products Manufacturing Group (IPMG) under the direction of the Food and Drug Administration. The program launched on March 1, 2006, at the beginning of the annual meeting of the American Academy of Dermatology.
Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication used to treat skin diseases like harlequin-type ichthyosis, and lamellar ichthyosis, and severe cystic acne or moderate acne that is unresponsive to antibiotics. [6]
The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services.The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines ...
Accutane causes the skin on the lips to shed so quickly that it can cause thick, chunky flakes to come off, which can worsen and become red if you pick the skin off, says Goldman. He recommends ...
Isotretinoin (formerly Accutane) helps control sebum production to reduce breakouts. Some people who take it may notice signs of hair thinning, a lack of new hair growth or more hair fallout than ...
Food and Drug Administration Amendments Act of 2007; Long title: To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes.